Subscribe to Newsletter
Subspecialties Imaging & Diagnostics, Retina, Basic & Translational Research

Alzheimer's Window

Accounting for around two thirds of all dementia cases in older people, Alzheimer’s disease (AD) places a huge burden not only on patients but also their carers and health systems all over the world. Research into novel treatments is ongoing, but the development of new tools to enable earlier diagnosis is another key focus.

Cerebral microvascular changes are increasingly linked to AD and also mild cognitive impairment (MCI) – a potential early-warning sign of AD, but measurement of such changes in the brain is challenging. Researchers at Duke University in North Carolina, USA, decided to investigate how closely the microvascular changes seen in the brain would be mirrored in the retina. To that end, the group used optical coherence tomography angiography (OCT-A) to image 90 eyes from 52 AD participants, 79 eyes from 41 MCI participants, and 269 eyes from 142 healthy controls (1). The results? The team observed significantly decreased VD and PD (in 3 × 3-mm and 6 × 6-mm scans) using ETDRS subfields in AD participants when compared with MCI and control participants. However, the researchers did not see a significant difference between MCI and healthy controls.

“The goal is to one day be able to diagnose Alzheimer’s disease in the very early stages."

Notably, the study excluded patients with other diseases, such as non-Alzheimer’s dementia, high blood pressure, glaucoma and diabetes, so it is unknown whether the differences seen in OCT-A are unique to AD. Nevertheless, the researchers' objective remains unchanged. “The goal is to one day be able to diagnose Alzheimer’s disease in the very early stages,” says corresponding author Sharon Fekrat, Professor of Ophthalmology at Duke University.

For now, the team will continue collecting longitudinal data, as well as studying larger populations, both of which will be crucial in understanding how the retina’s microvascular changes as the disease progresses. Moreover, Fekrat emphasises that, though OCT-A imaging may not offer the early diagnosis they were looking for, all is not lost: “We may have a non-invasive, inexpensive, and quick way to screen large numbers of people for Alzheimer’s disease and enter these individuals into clinical trials,” she says. And that can only be good news for other teams investigating potential therapies.

Receive content, products, events as well as relevant industry updates from The Ophthalmologist and its sponsors.

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

  1. SP Yoon et al., “Retinal Microvascular and Neurodegenerative Changes in Alzheimer’s Disease and Mild Cognitive Impairment Compared with Control Participants”, Ophthalmol Retina (2019).
About the Author
Ramona Howard

Zoology student at The University of Sheffield with an interest in Science Communication.

Related Case Studies
Business & Profession Glaucoma
TrabEx Pro: The Next Level in MIGS

| Contributed by MST

The Missing Piece of the Dry Eye Puzzle

| Contributed by Quidel

Uncovering Ocular Comorbidity

| Contributed by Quidel

Related Product Profiles
Uncover the Unique DNA of SPECTRALIS®

| Contributed by Heidelberg Engineering

Subspecialties Cornea / Ocular Surface
Tear Osmolarity – Empowering. Established. Essential.

| Contributed by TearLab

Subspecialties Retina
ForeseeHome® – remote monitoring to help detect wet AMD earlier and improve outcomes

| Contributed by Notal Vision

Product Profiles

Access our product directory to see the latest products and services from our industry partners

Here
Most Popular
Register to The Ophthalmologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine

Register

Disclaimer

The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: